CSG's Earnings Day: Production Numbers Take Center Stage After Short-Seller Assault

Czechoslovak Group releases first quarterly earnings since Amsterdam listing and Hunterbrook Media attack, with investors seeking proof of manufacturing capacity and growth.

For the Czechoslovak Group, Wednesday’s first-quarter report is more than a routine check-in. It is the first financial disclosure since its Amsterdam listing in January – and the first since a damaging short-seller attack sent the stock reeling. With the share price languishing near €16.34, down roughly 52% from its 52-week peak, management faces intense pressure to back up its denials with hard data.

The assault came in early May from Hunterbrook Media, which accused the Czech defence group of merely refurbishing old ammunition rather than manufacturing new rounds. The allegations also questioned transparency around the IPO and certain shareholder arrangements. CSG hit back with two formal rebuttals, calling the report a selective reading of public information designed to benefit a related short position. The company has since broken off direct dialogue with the research house. The market reaction was brutal: a single-day drop of over 13%, followed by a 24% monthly decline. At €16.27 the stock now trades far below its €25 IPO price.

Ahead of the earnings release, CSG has tried to build a counter-narrative with operational facts. In the first quarter it fully settled a €275 million receivable from the sale of non-core divisions – Mobility, Perazzi and Healthcare – a move that sharpens the focus on defence and aviation. On the factory floor, the company is pushing ahead with capacity expansion: new production lines in Slovakia will add 70,000 rounds of ammunition annually, part of a broader plan to lift total capacity by 20% by the end of 2026. Investors will be looking for concrete production figures in the Q1 report to disprove Hunterbrook’s claim that CSG is not a genuine manufacturer.

The group’s fundamental track record offers a strong base. Full-year 2025 revenue jumped nearly 72% to €6.74 billion, while adjusted EBIT reached €1.6 billion for a margin of 24.1%. For 2026 management targets revenue of €7.4–7.6 billion and an adjusted EBIT margin of 24–25%, stepping up to 26–28% over the medium term. The Q1 figures will provide the first reality check on that trajectory. One additional headwind: IPO-related costs will land in the first quarter, and whether management highlights adjusted earnings excluding those one-off charges will influence how the market reads the results.

Beyond the earnings, two recent developments underline CSG’s operational momentum. In April it secured a roughly €250 million contract to supply 155mm artillery ammunition to a European customer. And in late March it acquired a 49% stake in Austrian munitions specialist Hirtenberger Defence Systems, a deal still awaiting regulatory approval. Both moves reinforce the group’s position in a European defence market that the EU Commission expects to spend around €392 billion this year alone, with stockpiles needing years to replenish.

Analyst sentiment remains uniformly bullish. All nine covering the stock rate it a buy, with JPMorgan’s price target at €40 and the consensus at €35.40 – implying significant upside from current levels. The rating agencies have also lent support: Moody’s upgraded CSG’s secured debt to Baa3, while Fitch affirmed its BBB- rating with a stable outlook, lowering financing costs and widening the pool of potential institutional investors.

The stakes could hardly be higher for Wednesday’s release. With the stock hovering just above its 52-week low of €15.73, there is little room for disappointment. CSG has promised hard numbers that challenge the short-seller narrative. Whether it delivers will determine if the defence boom narrative – or the Hunterbrook shadow – dominates the next chapter for the stock.